Lenvatinib Plus Paclitaxel as Second‐Line Therapy for Advanced Gastric Cancer Patients: A Dose Escalation Exploratory Study (Adv. Sci. 40/2025)

Second-Line TherapyFor anti-angiogenic tyrosine kinase inhibitors as second-line treatment in gastric cancer, available biomarker is still unavailable.In their Research Article (DOI: 10

Publication Details

Journal
Advanced Science
Published
2025-10-01
DOI
https://doi.org/10.1002/advs.71957
Primary Topic
Photonic and Optical Devices
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Lenvatinib Plus Paclitaxel as Second‐Line Therapy for Advanced Gastric Cancer Patients: A Dose Escalation Exploratory Study (Adv. Sci. 40/2025)

Advanced Science
Photonic and Optical Devices
article

Lenvatinib Plus Paclitaxel as Second‐Line Therapy for Advanced Gastric Cancer Patients: A Dose Escalation Exploratory Study (Adv. Sci. 40/2025)

article en

Abstract

Second-Line TherapyFor anti-angiogenic tyrosine kinase inhibitors as second-line treatment in gastric cancer, available biomarker is still unavailable.In their Research Article (DOI: 10

Advanced ScienceVol. 12(40)
Zero hunger
Openalex Percentile: Top 49%
Photonic and Optical Devices
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Lenvatinib Plus Paclitaxel as Second‐Line Therapy for Advanced Gastric Cancer Patients: A Dose Escalation Exploratory Study (Adv. Sci. 40/2025) · Advanced Science (2025) | TGRS Research Map | TGRS